Metagenomi Therapeutics (MGX) FCF Margin (2023 - 2026)
Metagenomi Therapeutics (MGX) reported FCF Margin of 1698.72% for Q1 2026, down 113826.0% year-over-year from N/an in Q1 2025, and down 176.27% quarter-over-quarter from 614.88% in Q4 2025.
Metagenomi Therapeutics (MGX) FCF Margin (2023 - 2026) Analysis & Trends
Metagenomi Therapeutics (MGX) has 4 years of FCF Margin data on file, last reported at 1698.72% in Q1 2026.
- FCF Margin for Q1 2026 came in at 1698.72%, down 113826.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 391.99% (down 16101.0% YoY), and the FY2025 annual result was 354.88%, down 14036.0% from the prior year.
- FCF Margin slipped to 1698.72% in Q1 2026 per MGX's latest filing, from 614.88% in the prior quarter.
- Over five years, FCF Margin peaked at 132.36% in Q2 2024 and troughed at 1698.72% in Q1 2026.
- A 4-year average of 401.56% and a median of 246.73% in 2025 frame the typical range for FCF Margin.
- The sharpest annual moves came in 2024 and 2026: FCF Margin soared 8831 bps in 2024, then slumped 113826 bps in 2026.
- A 4-year view of FCF Margin shows it stood at 180.09% in 2023, then plunged by 68 bps to 302.88% in 2024, then slumped by 103 bps to 614.88% in 2025, then sank by 176 bps to 1698.72% in 2026.
- Business Quant data shows MGX's FCF Margin at 1698.72% in Q1 2026, 614.88% in Q4 2025, and 245.8% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 821,726.73 Bn | 821,726.69 Bn | - | - |
| 2 | Belite Bio | 57,768.00 Bn | 57,768.00 Bn | - | - |
| 3 | Quantum Biopharma | 16,655.88 Bn | 16,655.88 Bn | - | - |
| 4 | Legend Biotech | 3,540.00 Bn | 3,539.71 Bn | 242.10 Mn | -3.98% |
| 5 | Evaxion A | 1,526.26 Bn | 1,526.24 Bn | - | - |
| 6 | Akari Therapeutics | 1,520.09 Bn | 1,520.09 Bn | - | - |
| 7 | Psyence Biomedical | 223.87 Bn | 223.87 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.47 Bn | 107.23 Bn | 2.59 Bn | 43.35% |
| 9 | Abivax | 91.22 Bn | 91.22 Bn | - | - |
| 10 | Metagenomi Therapeutics | 42.84 Mn | 42.84 Mn | - | -1,698.72% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1,698.72% |
| Dec 31, 2025 | -614.88% |
| Sep 30, 2025 | -245.80% |
| Jun 30, 2025 | -246.73% |
| Mar 31, 2025 | -560.46% |
| Dec 31, 2024 | -302.88% |
| Sep 30, 2024 | -224.26% |
| Jun 30, 2024 | -132.36% |
| Mar 31, 2024 | -275.70% |
| Dec 31, 2023 | -180.09% |
| Sep 30, 2023 | -244.39% |
| Jun 30, 2023 | -220.67% |
| Mar 31, 2023 | -273.34% |